EP3703065A1 — Application unlock using a connected physical device and transfer of data therebetween
Assigned to Novartis AG · Expires 2020-09-02 · 6y expired
What this patent protects
According to one embodiment, a system includes a medical device configured to provide a function to a user, communicate via a wireless communication channel with one or more other devices, and send a signal to shift a medical device application from a locked state to an unlocked …
USPTO Abstract
According to one embodiment, a system includes a medical device configured to provide a function to a user, communicate via a wireless communication channel with one or more other devices, and send a signal to shift a medical device application from a locked state to an unlocked state. The system also includes a computing device having wireless communication channels and a processor and logic integrated with and/or executable by the processor. The logic is configured to cause the computing device to communicate with the medical device, execute the medical device application, and shift from the locked state to the unlocked state in response to receiving the signal from the medical device. Core functionality of the medical device application is disabled when the medical device application is in the locked state, and some functionality applicable to the medical device is enabled when the medical device application is in the unlocked state.
Drugs covered by this patent
- glycopyrrolate (Glycopyrrolate) · Yonsei University
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.